FDA clears drug for bladder control from UCB, Pfizer

11/3/2008 | Bloomberg · WebMD

The FDA granted approval for Toviaz, a once-daily drug from UCB and Pfizer designed to treat adults with overactive bladders. The clearance is based on two 12-week trials showing the medicine's efficacy versus placebo in decreasing urinary frequency. Pfizer paid as much as $210 million in April 2006 to secure the U.S. rights to Toviaz from Schwarz Pharma of Germany.

View Full Article in:

Bloomberg · WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY